(+)-Tomoxetine hydrochloride | CAS#82857-39-4

MedKoo Cat#: 529198 | Name: (+)-Tomoxetine hydrochloride

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

(+)-Tomoxetine hydrochloride is a bioactive chemical with applications towards treating multiple cognitive disabilities.

Chemical Structure

(+)-Tomoxetine hydrochloride

CAS#82857-39-4

Theoretical Analysis

MedKoo Cat#: 529198

Name: (+)-Tomoxetine hydrochloride

CAS#: 82857-39-4

Chemical Formula: C17H22ClNO

Exact Mass: 291.1390

Molecular Weight: 291.82

Elemental Analysis: C, 69.97; H, 7.60; Cl, 12.15; N, 4.80; O, 5.48

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 500.00	2 Weeks
50mg	USD 1,750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

(+)-Tomoxetine hydrochloride

IUPAC/Chemical Name

Benzenepropanamine, N-methyl-gamma-(2-methylphenoxy)-, hydrochloride, (gammaS)-

InChi Key

LUCXVPAZUDVVBT-LMOVPXPDSA-N

InChi Code

InChI=1S/C17H21NO.ClH/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15;/h3-11,17-18H,12-13H2,1-2H3;1H/t17-;/m0./s1

SMILES Code

CC1=CC=CC=C1O[C@H](C2=CC=CC=C2)CCNC.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 291.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Warner CB, Ottman AA, Brown JN. The Role of Atomoxetine for Parkinson Disease-Related Executive Dysfunction: A Systematic Review. J Clin Psychopharmacol. 2018 Dec;38(6):627-631. doi: 10.1097/JCP.0000000000000963. PubMed PMID: 30346335. 2: Wadman M. Drug pair shows promise for treating sleep apnea. Science. 2018 Sep 21;361(6408):1174-1175. doi: 10.1126/science.361.6408.1174. PubMed PMID: 30237332. 3: Barbaros MB, Can ÖD, Üçel Uİ, Turan Yücel N, Demir Özkay Ü. Antihyperalgesic Activity of Atomoxetine on Diabetes-Induced Neuropathic Pain: Contribution of Noradrenergic and Dopaminergic Systems. Molecules. 2018 Aug 19;23(8). pii: E2072. doi: 10.3390/molecules23082072. PubMed PMID: 30126223; PubMed Central PMCID: PMC6222656. 4: Sharma A. Update on Common Psychiatric Medications for Children. Pediatr Ann. 2018 Aug 1;47(8):e311-e316. doi: 10.3928/19382359-20180702-01. Review. PubMed PMID: 30102754. 5: Osland ST, Steeves TD, Pringsheim T. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev. 2018 Jun 26;6:CD007990. doi: 10.1002/14651858.CD007990.pub3. Review. PubMed PMID: 29944175. 6: Moreira-Maia CR, Massuti R, Tessari L, Campani F, Akutagava-Martins GC, Cortese S, Rohde LA. Are ADHD medications under or over prescribed worldwide?: Protocol for a systematic review and meta-analysis. Medicine (Baltimore). 2018 Jun;97(24):e10923. doi: 10.1097/MD.0000000000010923. Review. PubMed PMID: 29901582; PubMed Central PMCID: PMC6023876. 7: Oh Y, Joung YS, Jang B, Yoo JH, Song J, Kim J, Kim K, Kim S, Lee J, Shin HY, Kwon JY, Kim YH, Jeong B. Efficacy of Hippotherapy Versus Pharmacotherapy in Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial. J Altern Complement Med. 2018 May;24(5):463-471. doi: 10.1089/acm.2017.0358. Epub 2018 Apr 11. PubMed PMID: 29641212. 8: Meyers KJ, Upadhyaya HP, Goodloe R, Kryzhanovskaya LA, Liles-Burden MA, Kellier-Steele NA, Mancini M. Evaluation of dystonia in children and adolescents treated with atomoxetine within the Truven MarketScan database: a retrospective cohort study. Expert Opin Drug Saf. 2018 May;17(5):467-473. doi: 10.1080/14740338.2018.1462333. Epub 2018 Apr 13. PubMed PMID: 29625537. 9: Schottenfeld RS, Chawarski MC, Sofuoglu M, Chooi WT, Zaharim NM, M Yasin MA, Ahmad I, Syed Jaapar SZ, Vicknasingam BK. Atomoxetine for amphetamine-type stimulant dependence during buprenorphine treatment: A randomized controlled trial. Drug Alcohol Depend. 2018 May 1;186:130-137. doi: 10.1016/j.drugalcdep.2018.01.017. Epub 2018 Mar 10. PubMed PMID: 29573648; PubMed Central PMCID: PMC5911201. 10: Snircova E, Marcincakova Husarova V, Ondrejka I, Hrtanek I, Farsky I, Nosalova G. QTc prolongation after ADHD medication. Neuro Endocrinol Lett. 2018 Feb;38(8):549-554. PubMed PMID: 29504733. 11: Nishitomi K, Yano K, Kobayashi M, Jino K, Kano T, Horiguchi N, Shinohara S, Hasegawa M. Systemic administration of guanfacine improves food-motivated impulsive choice behavior primarily via direct stimulation of postsynaptic α(2A)-adrenergic receptors in rats. Behav Brain Res. 2018 Jun 1;345:21-29. doi: 10.1016/j.bbr.2018.02.022. Epub 2018 Feb 21. PubMed PMID: 29476896. 12: Stuhec M, Locatelli I. Attention deficit hyperactivity disorder pharmacotherapy in Slovenian adults: a population-based study. Int J Clin Pharm. 2018 Apr;40(2):341-344. doi: 10.1007/s11096-018-0605-0. Epub 2018 Feb 21. PubMed PMID: 29468526. 13: Matthews PRL, Horder J, Pearce M. Selective noradrenaline reuptake inhibitors for schizophrenia. Cochrane Database Syst Rev. 2018 Jan 25;1:CD010219. doi: 10.1002/14651858.CD010219.pub2. Review. PubMed PMID: 29368813. 14: Hoxhaj E, Sadohara C, Borel P, D'Amelio R, Sobanski E, Müller H, Feige B, Matthies S, Philipsen A. Mindfulness vs psychoeducation in adult ADHD: a randomized controlled trial. Eur Arch Psychiatry Clin Neurosci. 2018 Jun;268(4):321-335. doi: 10.1007/s00406-018-0868-4. Epub 2018 Jan 22. PubMed PMID: 29356899. 15: Toriumi K, Tanaka J, Mamiya T, Alkam T, Kim HC, Nitta A, Nabeshima T. Shati/Nat8l knockout mice show behavioral deficits ameliorated by atomoxetine and methylphenidate. Behav Brain Res. 2018 Feb 26;339:207-214. doi: 10.1016/j.bbr.2017.11.040. Epub 2017 Dec 2. PubMed PMID: 29203337. 16: Luan R, Mu Z, Yue F, He S. Efficacy and Tolerability of Different Interventions in Children and Adolescents with Attention Deficit Hyperactivity Disorder. Front Psychiatry. 2017 Nov 13;8:229. doi: 10.3389/fpsyt.2017.00229. eCollection 2017. PubMed PMID: 29180967; PubMed Central PMCID: PMC5694170. 17: Cohen JM, Hernández-Díaz S, Bateman BT, Park Y, Desai RJ, Gray KJ, Patorno E, Mogun H, Huybrechts KF. Placental Complications Associated With Psychostimulant Use in Pregnancy. Obstet Gynecol. 2017 Dec;130(6):1192-1201. doi: 10.1097/AOG.0000000000002362. PubMed PMID: 29112657; PubMed Central PMCID: PMC5709205. 18: Hernaus D, Quaedflieg CWEM, Offermann JS, Casales Santa MM, van Amelsvoort T. Neuroendocrine stress responses predict catecholamine-dependent working memory-related dorsolateral prefrontal cortex activity. Soc Cogn Affect Neurosci. 2018 Jan 1;13(1):114-123. doi: 10.1093/scan/nsx122. PubMed PMID: 29087511; PubMed Central PMCID: PMC5793733. 19: Williams T, Hattingh CJ, Kariuki CM, Tromp SA, van Balkom AJ, Ipser JC, Stein DJ. Pharmacotherapy for social anxiety disorder (SAnD). Cochrane Database Syst Rev. 2017 Oct 19;10:CD001206. doi: 10.1002/14651858.CD001206.pub3. Review. PubMed PMID: 29048739. 20: Gandhi R, Narang P, Lippmann S. Urinary Hesitancy Associated With Atomoxetine. Prim Care Companion CNS Disord. 2017 Sep 14;19(5). pii: 17l02095. doi: 10.4088/PCC.17l02095. PubMed PMID: 28930379.